HRTIS — Herantis Pharma Oyj Share News
0.000.00%
Last trade - 00:00Brief: Herantis Pharma Oyj Says Commencing A Rights Issue, Offers Up To 4,831,426 New Shares For Subscription
Brief: Herantis Pharma Successfully Completes Directed Share Issue Raising EUR 1.46 Million
Brief: Herantis Pharma Says Contemplating Carrying Out A Directed Share Issue And Rights Issue
Brief: Herantis Pharma: Successful HER-096 Initial Results With Nanoform Technology
Brief: Herantis Pharma H2 Loss For Period Slightly Widens To EUR 4.8 Million
Brief: Herantis Pharma Appoints Frans Wuite As Interim CEO
Brief: Herantis Pharma Updates On New Biomarker Program
Brief: Herantis Pharma Announces Successful Results With Nanoform Technology
Brief: Herantis Pharma H1 Loss For Period Widens To EUR 7.9 Mln
Brief: Herantis Pharma To Focus On CDNF And xCDNF Programs
Brief: Herantis Pharma H2 Loss Unchanged At EUR 4.7 Mln
Brief: Herantis: Inconclusive Results From Phase II Study With Lymfactin In BCRL
Brief: Herantis Pharma And Nanoform Enter Collaboration Agreement
Brief: Herantis Pharma Completes Private Placement Raising EUR 8 Mln
Brief: Herantis Pharma Launches Accelerated Bookbuilding Process To Raise Min Of EUR 6.5 Mln Through Private Placement Of New Shares
Brief: Herantis Pharma And Nanoform Sign A Letter Of Intent For Collaboration
Brief: Herantis Pharma Announces Favorable 24-Month Follow-Up Review From Phase I Lymfactin Trial In Breast Cancer Associated Lymphedema
Brief: Herantis Pharma Evaluates Alternatives To Finance Its Research & Development Pipeline
Brief: Herantis Appoints Tone Kvåle As Chief Financial Officer